FDA approves Recarbrio for treatment of bacterial pneumonias
from European Pharmaceutical Review
The U.S. Food and Drug Administration has approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in patients 18 years of age and older. The approval of this indication is based on limited clinical safety and efficacy data.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063